World Cancer Market Analysis and Reports | Italy Conference Series

Market Analysis - World Cancer 2017

Summary

The pace of change in cancer care is accelerating. A cluster of innovative treatments often combined with other new or existing medicines are emerging from the research and development pipeline. Many are for tumour types associated with low survival rates and where patients have limited options. The landscape is shifting rapidly, bringing new complexity to oncologists, payers and governments who all look to provide appropriate care to patients while ensuring the sustainability of healthcare systems. Earlier diagnosis, longer treatment duration and increased effectiveness of drug therapies are contributing to rising levels of spending on medicines for cancer care

Brief Report of Cancer & Oncology field in various aspects

Cancer Diagnostics Market

This report studies the global cancer diagnostics market for the forecast period of 2015 to 2020. This market is expected to reach $13.1 Billion by 2020 from $7.1 Billion in 2015, and is poised to grow at a CAGR of 12.9% during the forecast period.

                  

Some of the major players in the global cancer diagnostics system market include Agilent Technologies, Thermo Fisher Scientific,  Illumina, Becton, Dickinson and Company ,  GE Healthcare , QIAGEN , Abbott Laboratories, Roche Diagnosticsm, Siemens Healthcare, Philips Healthcare and C.R. Bard among others.

Global Oncology/Cancer Drugs Market

Annual global growth in the oncology drug market is expected to be 7.5 – 10.5 percent through 2020, reaching $150 billion. Wider utilization of new products—especially immunotherapies—will drive much of the growth, offset by reduced use of some existing treatments with inferior clinical outcomes. Global cancer drugs market is primarily driven by growing incidences of target disease such as lung cancer, breast cancer, cervical cancer, etc. across the globe. Other major driving factors are increasing research and development on biological and targeted drug therapies for the treatment of cancer coupled along with the expiration of patents

             

It is expected to reach $111.9 billion by 2020, registering a CAGR of 7.1% during the forecast period 2014 to 2020. Recent progress in biological therapies has widened the scale of therapeutic targets for treatment of cancer with the identification of tumour cell specific genes. Immunotherapies/ biologics are emerging as potential therapies to find the permanent cure for various cancer types.

Cancer Therapy Market

Rise in cancer incidences and access to modern therapeutics, population of aged people, Increase in innovations, improvements and approvals promote growth of the market. Furthermore, efficiency and High process magnetize manufactures also contribute to the growth of the market .Major restraints are high price of therapies, change in reimbursement policies, and challenges faced in clinical trials.

The global Cancer therapy market is estimated to grow at 17.6% CAGR to reach $52.2billion by 2021.

                         

Market is segmented based on therapies i. e Targeted cancer therapies (Hormone therapy, Signal transduction inhibitors,  gene expression modulators, Apoptosis inducers etc.), Hormone therapies( Forms of hormone therapy) , immunotherapy( Monoclonal antibodies, Cancer vaccines, Non-specific immunotherapies) ,Chemotherapy.

Summary

The pace of change in cancer care is accelerating. A cluster of innovative treatments often combined with other new or existing medicines are emerging from the research and development pipeline. Many are for tumour types associated with low survival rates and where patients have limited options. The landscape is shifting rapidly, bringing new complexity to oncologists, payers and governments who all look to provide appropriate care to patients while ensuring the sustainability of healthcare systems. Earlier diagnosis, longer treatment duration and increased effectiveness of drug therapies are contributing to rising levels of spending on medicines for cancer care.